Obstructive sleep apnoea: a diabetologist’s perspective

ABD A TAHRANI

Abstract
Obstructive sleep apnoea (OSA) is very common in patients with type 2 diabetes (T2D), which is unsurprising given that obesity is a major risk factor for both conditions. OSA has been associated with impaired quality of life, many cardiovascular disease (CVD) risk factors and cardiovascular disease in general. Continuous positive airway pressure treatment has beneficial impacts on CVD risk factors and CVD. However, the true impact of OSA in patients with T2D remains unclear. The International Diabetes Federation recommended routine screening for OSA in patients with T2D, but two-thirds of diabetes healthcare professionals were unaware of these recommendations. The aim of this review is to attempt to answer the following questions. Is OSA diagnosis and treatment important in patients with T2D and why? What is the relevance of OSA to the practising diabetologist?

Key words: obstructive sleep apnoea, type 2 diabetes, hypertension, cardiovascular disease, hyperlipidaemia, quality of life

Introduction
Obstructive sleep apnoea (OSA) affects 17–26% of men and 9–28% of women in population-based epidemiological studies. It is characterised by upper airway instability during sleep that causes recurrent complete or partial upper airway obstruction resulting in recurrent episodes of either complete (apnoea) or partial (hypopnea) cessation of airflow. Apnoeas and hypopneas are associated with recurrent oxygen desaturations, cyclical changes in intrathoracic pressure (as the patient attempts to breathe against a blocked airway), increased blood pressure (BP), heart rate and sympathetic activity, and recurrent micro-arousals (due to attempts to open the obstructed airways) that cause sleep fragmentation and disturb the sleep architecture. The apnoea hypopnoea index (AHI) represents the average number of apnoea and hypopnoea episodes/hour during sleep: ≥5 events/hour is consistent with a diagnosis of OSA, while AHI cut-offs of 15 and 30 indicate moderate and severe OSA. Other measures of OSA include the Oxygen Desaturation Index (ODI), the average number of oxygen desaturations/hour of sleep (3% or 4% depending on the definition used), the lowest nocturnal oxygen saturations and the time spent with oxygen saturation <90%. Weight loss and continuous positive airway pressure (CPAP) are the mainstay treatments of OSA. Mandibular advancement devices can also be used in patients with mild OSA or those intolerant to CPAP.

Snoring and witnessed apnoeas are common symptoms of OSA, with snoring reported in 95% of patients. Excessive daytime sleepiness (EDS), although associated with OSA, seems to have stronger associations with depression and the metabolic syndrome. Other symptoms such as choking, insomnia, nocturia, sweating, fatigue, morning headache, erectile dysfunction and autonomic symptoms have been reported. Many of these are also common in type 2 diabetes (T2D) and contribute to the burden of disease. OSA should be considered as a cause of such symptoms in patients with T2D after ruling out hypoglycaemia or hyperglycaemia as CPAP treatment can improve these symptoms.

Obesity is a common risk factor for OSA and T2D, and the prevalence of OSA is high in people with T2D (8.5–85%, with 23.8–70% for moderate-to-severe OSA). This wide range reflects differences in the population examined (primary versus secondary care, ethnicities, gender, obesity, etc), the methods used to diagnose OSA (patients’ records, questionnaires, oximetry, portable multi-channel cardiovascular monitoring devices or ‘gold standard’ polysomnography) and the OSA definitions used (AHI versus ODI, different cut-offs). It is not clear, however, whether the prevalence of OSA in patients with T2D is higher than expected for patients with similar adiposity but without T2D. A recent cross-sectional analysis of the European Sleep Apnea Cohort (ESADA; n=6,616) suggested that the prevalence of T2D, adjusted for obesity and other potential confounders, increased with worsening OSA: odds ratio (OR) 1.33 (95% CI 1.04 to 1.72) for mild OSA, 1.73 (95% CI 1.33 to 2.25) for moderate OSA and 1.87 (95% CI 1.45 to 2.42) for severe OSA (p<0.001).

In 2008 the International Diabetes Federation (IDF) recommended routine screening for OSA in patients with T2D, but two-thirds of diabetes healthcare professionals were unaware of these recommendations or that the local diabetes guidelines did not incorporate assessment for OSA in those at risk. Nonetheless, the impact of OSA in patients with T2D, how to screen and the benefits of screening are still unclear.
The impact of OSA on glucose metabolism and pre-diabetes and the consequences of having OSA in general population studies has been reviewed elsewhere.4,18 The aim of this article is to attempt to answer the following questions: Is OSA diagnosis and treatment important in patients with T2D and why? What is the relevance of OSA to the practising diabetologist?

**OSA is a risk factor for T2D**

Many cross-sectional studies in the general population19-28 and patients with T2D29,30 showed an association between OSA and insulin resistance, but others did not31-33. These conflicting results are partly due to variation in the population examined, sample size (studies that did not show an association were smaller)14 or because of variation in EDS, which is associated with insulin resistance.34,35 Obesity did not explain fully the association between OSA and insulin resistance; many studies adjusted for obesity measures, OSA was associated with insulin resistance in lean men, and OSA can be caused by conditions other than obesity (e.g. acromegaly).36-38

One longitudinal study showed that OSA, AHI, ODI and minimal nocturnal oxygen saturations were independent predictors of worsening insulin resistance (>75th percentile of change in HOMA-IR) over an 11-year follow-up period after adjustment for age, baseline body mass index (BMI), hypertension, BMI change over follow-up and CPAP.39

The impact of OSA on β-cell dysfunction in humans is limited. A cross-sectional study showed that OSA was associated with impaired β-cell function in patients with T2D or without diabetes.40

In addition, OSA is associated with non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH).27,41

OSA predicts the development of incident T2D independently of age, obesity or other confounders,39,42-46 and 8 hours/night of CPAP improved post-load glycaemia (oral glucose tolerance test) insulin sensitivity, 24-hour BP and norepinephrine levels in a randomised placebo-controlled trial.47 However, this study was conducted in the laboratory environment to ensure the high compliance with CPAP, and the effects of CPAP on the incidence of T2D in uncontrolled settings remains to be determined.

**OSA is associated with worse glycaemic control in patients with T2D**

Cross-sectional studies show that OSA is associated with poorer glycaemic control, despite adjustments for age, sex, race, BMI, number of medications, exercise, diabetes duration and total sleep time.15,48-50 Lower nocturnal oxygen saturations were associated with higher HbA1C values in one study,51 but elsewhere there was no association between OSA and HbA1C,52 probably because only 22% of participants had full polysomnography and the duration of the sleep study was just 4 hours.53 Prospective studies assessing the impact of OSA on glycaemic measures longitudinally in patients with T2D are lacking.

**OSA is associated with hypertension**

Extensive epidemiological studies and interventional trials in the general population, but only limited data in patients with T2D, have associated OSA with hypertension and non-dipping BP.4,14,18 The Wisconsin Sleep Cohort Study found adjusted ORs for incident hypertension between 1.42 and 2.89 with increasing AHI (versus AHI=0 at baseline, p<0.002 for the trend).54 Long-term (7 years) mild and moderate OSA (versus AHI <5) increased the risk of incident nocturnal non-dipping BP about threefold and fourfold, respectively, in a subgroup of patients.55 A large cross-sectional study showed that OSA was more prevalent in T2D patients with awake BP ≥135/85 mmHg or asleep BP ≥120/70 mmHg compared with lower BP,56 suggesting a link between OSA and hypertension in T2D.

**OSA is associated with hyperlipidaemia**

A mechanistic link between OSA and hyperlipidaemia is plausible as chronic intermittent hypoxia could lead to the generation of stearoyl-coenzyme A desaturase-1, oxidative stress, peroxidation of lipids and sympathetic activation.57 However, cross-sectional studies were not consistent mainly due to differences in the population examined, study designs and the impact of CPAP.57,58 A meta-analysis of 64 studies showed that OSA was associated with higher total cholesterol, higher low-density lipoprotein (LDL), higher triglycerides and lower high-density lipoprotein (HDL), while AHI correlated positively with triglycerides and negatively with HDL levels only.58 The association between OSA/AHI and triglycerides is obesity independent.59 Longitudinal studies are lacking.

**OSA is associated with cardiovascular disease**

**General population**

OSA has been associated with a larger atherosclerotic plaque volume, with AHI correlating positively with plaque volume.50,61 OSA increased the risk of acute myocardial infarction overnight, supporting a role for nocturnal OSA events in the development of cardiovascular disease (CVD).62 Prospective observational studies (3–10 years of follow-up) have shown that OSA predicts the development of incident CVD, with adjusted OR/HR for incident CVD of 1.97–4.9.63-68

Age and gender may modulate the relationship between OSA and incident CVD, as suggested by observational cohort studies in which OSA predicted incident coronary artery disease (CAD) only in men aged <70 years and predicted heart failure only in men;58 or was associated with stroke incidence only in men.69 However, a study that included women showed that untreated OSA predicted a combined outcome of incident stroke and CAD, driven only by increased risk of stroke.70

**Patients with T2D**

AHI was associated with a history of stroke (adjusted OR 2.57, 95% CI 1.03 to 6.42) but not with CAD in a cross-sectional analysis from the Look AHEAD study.71 A prospective observational study of 132 consecutive asymptomatic patients with T2D and OSA showed that OSA was associated with incident CAD (adjusted HR 2.2, 95% CI 1.2 to 3.9, p=0.01) and heart failure (adjusted HR 3.5, 95% CI 1.4 to 9.0; p<0.01) over a median follow-up of 4.9 years.72

**OSA is associated with diabetes-related microvascular complications**

The link between OSA and microvascular complications is plausible.
Intermittent hypoxaemia can result in increased oxidative and nitrosative stress, poly-(ADP-ribose) polymerase activation, increased advanced glycation end products, protein kinase C activation and inflammation in patients with and without diabetes – all of which can result in endothelial dysfunction and microvascular disease.4,11,14

OSA and diabetic retinopathy
In Japanese patients undergoing vitreous surgery for advanced diabetic retinopathy (DR), lower oxygen saturations were associated with proliferative DR after adjustment for age, HbA1c and hypertension.99 Cross-sectional data from the UK suggest that OSA may be independently associated with DR and maculopathy.10,75 Longitudinally, patients with OSA were more likely to develop pre-proliferative/proliferative DR than those with T2D.75

OSA and diabetic nephropathy
In a cross-sectional study of Japanese patients with T2D, ODI ≥5 was independently associated with microalbuminuria in women but not in men after adjustment for confounders.74 In another cross-sectional study, OSA was associated with diabetic nephropathy in patients with T2D (adjusted OR 2.64, 95% CI 1.13 to 6.16, p=0.02).77 Longitudinally, the decline in the estimated glomerular filtration rate (eGFR) was greater in patients with OSA than in those without (p=0.003). OSA was an independent predictor of study end eGFR and eGFR decline.

OSA is associated with impaired quality of life
Several cross-sectional studies showed that OSA, its severity and nocturnal hypoxaemia were associated with worse quality of life (QoL) independent of EDS.79,80 This association might be modulated by age.79

OSA is associated with increased risk of road traffic accidents
There is extensive evidence using driving stimulators and insurance databases showing an association between OSA and road traffic accidents (RTA) and that CPAP treatment lowers the risk of RTA in patients with OSA.1,81-83 T2D is also associated with an increased risk of RTA, but whether having both conditions increases the risk of RTA more than either one alone is unknown.

OSA is associated with erectile dysfunction
OSA and erectile dysfunction (ED) share many risk factors and their severity often goes in parallel.84 In one randomised controlled trial (RCT) (n=27), 1 month of CPAP improved ED, but the findings are difficult to interpret as the control group in this study received no treatment rather than sham CPAP; also, the study was unblended and its outcome was self-reported.85 Other uncontrolled/observational studies suggested beneficial effects of CPAP on ED, and RCTs showed that sildenafil was superior to CPAP for managing ED.84,86-88

Impact of CPAP on glucose metabolism, CVD and QoL
CPAP improved insulin sensitivity in patients with and without T2D in non-randomised trials89,90 and in meta-analyses,89,91,92 especially for patients using CPAP >4 hours/night.93 Uncontrolled studies in patients with T2D89,94-97 showed that CPAP improves postprandial hyperglycaemia,94 glycaemic variability95 and/or HbA1c.94,98 However, RCTs examining the impact of CPAP on glycaemic measures are limited and showed conflicting results. One RCT showed no impact of 3 months of CPAP on HbA1c.99 This may have been due to true lack of effect, the sample size, the relatively short duration of treatment and issues with CPAP compliance (3.6 hours/night). Another RCT of CPAP vs. usual care in patients with Type 2 diabetes and moderate-severe OSA showed that CPAP had no effect on glycaemic control, but the glycaemic measures were relatively well-controlled at baseline before randomisation.100 However, another RCT of 50 patients with T2D and OSA showed that 6 months of CPAP resulted in greater reduction in HbA1c and insulin resistance compared to the control group.101 Meta-analyses showed that CPAP did not significantly improve HbA1c in patients with T2D, but these meta-analyses did not include the latest studies described above.92,102 As the association between OSA and HbA1c seems stronger during rapid eye movement (REM) sleep,103 CPAP might have more impact on HbA1c at this sleep stage; CPAP use of >4 hours/night may be required to improve HbA1c as REM occurs predominantly towards the end of the night. CPAP therefore cannot be recommended to improve glycaemic control in T2D and well-designed RCTs are needed.104

CPAP lowered BP in hypertensive patients with OSA in several RCTs and meta-analyses105-107 and resulted in nocturnal dipping in BP in patients with resistant hypertension.107 However, valsartan was superior to CPAP (difference in mean 24-hour BP −7.0 mmHg, 95% CI −10.9 to −3.1, p<0.001) in an 8-week randomised crossover study.108 CPAP was associated with a mean BP change of −6.81/−3.69 mmHg over 9–12 months in a retrospective cohort database study of patients with newly diagnosed OSA and pre-existing hypertension or T2D.109 CPAP lowered systolic and diastolic BP (149/80 mmHg to 140/73 mmHg, p=0.005/0.007) in another randomised trial.97 As yet, the impact of CPAP on incident hypertension is unclear.110 CPAP reduced total and LDL cholesterol and increased HDL cholesterol but had no effect on triglycerides in a meta-analysis of 29 trials.111 Another meta-analysis including only RCTs (n=6) showed that CPAP reduced total cholesterol (particularly in younger more obese patients and those who used CPAP for a longer period) without effects on other lipid parameters.112 Three months of CPAP had no effect on lipids in a RCT in patients with T2D, but lipids were well controlled at baseline.97 Overall, the impact of CPAP on lipids might be less relevant than that of lipid-lowering treatments.
CPAP was associated with a lower CVD incidence compared with no CPAP in some observational studies. Randomisation of 723 patients with AHI ≥20 and Epworth sleepiness score ≤10 to CPAP versus no CPAP for 4 years had no impact on the incidence of a composite of hypertension and CVD (OR 0.83, 95% CI 0.63 to 1.1; p=0.20). However, the combined outcome (but not CVD alone, perhaps due to a lack of events) was reduced in those who used CPAP ≥4 hours/night (OR 0.72, 95% CI 0.52 to 0.98; p=0.04). The impact of CPAP on CVD in patients with T2D remains unknown. On the one hand, the favourable impact of CPAP on CVD risk factors suggests that CPAP might lower CVD but, as the impact of CPAP on CVD risk factors may not be greater than currently available treatments, then CPAP might not have an additional benefit. RCTs are again needed to answer this question.

The impact of CPAP on microvascular complications in patient with T2D is limited to a small number of observational studies. In a cohort study from the UK, patients who were more compliant with CPAP had a lower progression of DR. A RCT assessing the impact of CPAP on maculopathy is currently ongoing. CPAP was also associated with less eGFR decline in an observational study from the UK. Uncontrolled studies suggest that 2–6 months of CPAP might improve vitality, social functioning, mental health, physical health and levels of independence, with the magnitude of improvement related to the baseline QoL impairment rather than OSA severity. However, another study found that the improvement in QoL on CPAP was similar irrespective of compliance.

Data in T2D are lacking.

Conclusions
OSA is very common in patients with T2D and is associated with impaired QoL, ED, CV risk factors, CVD and microvascular complications in patients with and without T2D. However, convincing evidence from RCTs in patients with T2D that CPAP treatment has a favourable impact on CVD, microvascular complications or QoL are still lacking. Evidence from general populations suggests that CPAP improves hypertension, hyperlipidaemia, insulin resistance, QoL and CVD. In addition, OSA symptoms are common in patients with T2D and CPAP will improve these symptoms.

Most diabetologists do not check for OSA in patients with T2D, despite its high prevalence in this population and despite a recommendation to do so by the IDF since 2008. This is further complicated by a lack of consensus regarding the best way to screen for OSA in patients with T2D and the lack of data regarding the impact of CPAP and cost-effectiveness, which raises further challenges for diabetologists. However, regardless of the impact of CPAP on diabetes-related outcomes, it is important to remember that OSA lowers the risk of RTA. In addition, diabetologists should be vigilant to diagnose OSA in patients with T2D in whom CPAP might have a favourable impact, such as patients with OSA-related symptoms or those with resistant hypertension or significant insulin resistance. Ongoing RCTs will clarify the impact of CPAP on diabetes-related outcomes, particularly glycaemic control and microvascular and macrovascular disease. In addition, several studies are examining the role of a number of biomarkers to aid screening for OSA in patients with T2D.

Conflict of interest None.

Disclosure The author is a clinician scientist supported by the National Institute for Health Research (NIHR) in the UK. The views expressed in this publication are those of the author and not necessarily those of the National Health Service, the NIHR or the Department of Health.

Funding No funding was received for the publication of this article.

References


89. Iftekhar IH, Hoyos CM, Phillips CL, Magalang UI. Meta-analyses of the association of sleep apnea with insulin resistance, and the effects of...